Protocol to generate traceable CAR T cells for syngeneic mouse cancer models.
STAR Protoc
; 5(1): 102898, 2024 Mar 15.
Article
en En
| MEDLINE
| ID: mdl-38367235
ABSTRACT
The efficacy of chimeric antigen receptor (CAR) T cell immunotherapy is limited by insufficient infiltration and activation of T cells due to the immunosuppressive tumor microenvironment. Preclinical studies with optimized mouse CAR T cells in immunocompetent mouse cancer models will help define the mechanisms underlying immunotherapy resistance. Here, we present a protocol for preparing mouse T cells and generating CAR T cells. We then detail procedures for testing their therapeutic efficacy and tracking them in a syngeneic mouse glioma model. For complete details on the use and execution of this protocol, please refer to Zhang et al.1.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Receptores Quiméricos de Antígenos
/
Glioma
Idioma:
En
Revista:
STAR Protoc
Año:
2024
Tipo del documento:
Article